AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36474395 — intervention group
Group type: COMPARATOR
Intervention: Curcumin only
Number of subjects: 90
Study 32463566 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (ATV) in uncontrolled SLE group
Number of subjects: 40
Study 32463566 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (ATV) in controlled SLE group
Number of subjects: 40
Study 35641967 — intervention group
Group type: EXPERIMENTAL
Intervention: A2E-loaded group
Number of subjects: 0
Study 35641967 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light irradiation group
Number of subjects: 0
Study 35641967 — intervention group
Group type: EXPERIMENTAL
Intervention: A2E-loaded + blue light irradiation group
Number of subjects: 0
Study 35641967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34641821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component exercise program related to cycling (MEPC)
Number of subjects: 100
Study 34641821 — intervention group
Group type: COMPARATOR
Intervention: Health and bicycle-related presentations (HRP)
Number of subjects: 100
Study 32757702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metalinguistic sentence combining (MSC) intervention during science class for a total of 400 min (20 sessions, 20 min each)
Number of subjects: 84
Study 32757702 — intervention group
Group type: COMPARATOR
Intervention: Typical science instruction
Number of subjects: 84
Study 34011583 — intervention group
Group type: EXPERIMENTAL
Intervention: Google Maps intervention for identifying work venues at 12-month and 18-month study visits
Number of subjects: 34
Study 34011583 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with high-risk women, male partners, health workers, and sex-worker managers
Number of subjects: 34
Study 32300524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dangguijagyag-san (EG)
Number of subjects: 240
Study 32300524 — intervention group
Group type: COMPARATOR
Intervention: Gamisoyo-san (ACG)
Number of subjects: 240
Study 32300524 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (PCG)
Number of subjects: 240
Study 33569576 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS181 (4.5 mg/day)
Number of subjects: 111
Study 33569576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 32718528 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 250 mg/day orally for 15 days
Number of subjects: 62
Study 32718528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 33598889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (4 mg)
Number of subjects: 198
Study 33598889 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (50 µg)
Number of subjects: 198
Study 33598889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dexamethasone and dexmedetomidine
Number of subjects: 198
Study 33598889 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of recovery 15 score with dexamethasone
Number of subjects: 198
Study 33598889 — intervention group
Group type: COMPARATOR
Intervention: Quality of recovery 15 score with dexmedetomidine
Number of subjects: 198
Study 32139280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 1 month of dual-antiplatelet therapy (DAPT) for 23 months
Number of subjects: 15936
Study 32139280 — intervention group
Group type: COMPARATOR
Intervention: Standard DAPT for 12 months followed by aspirin monotherapy
Number of subjects: 15936
Study 32139280 — intervention group
Group type: EXPERIMENTAL
Intervention: High pulse pressure (PP) group
Number of subjects: 15936
Study 36066991 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritoran (12 mg i.v. every 12 hours)
Number of subjects: 19
Study 36066991 — intervention group
Group type: COMPARATOR
Intervention: Intralipid (30 mL/h) plus vehicle
Number of subjects: 19
Study 34824180 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.5% with adrenaline 1:200000
Number of subjects: 30
Study 34824180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% with adrenaline and dexamethasone 8 mg
Number of subjects: 30
Study 32681239 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication use (28% of patients, n = 223)
Number of subjects: 1357
Study 32681239 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic loci associated with constant-severe pain
Number of subjects: 1357
Study 32681239 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant use
Number of subjects: 1357
Study 35193081 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Formula (EF) with added bMFGM
Number of subjects: 582
Study 35193081 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Formula (SF)
Number of subjects: 582
Study 35193081 — intervention group
Group type: COMPARATOR
Intervention: Experimental Formula (EF)
Number of subjects: 582
Study 35193081 — intervention group
Group type: COMPARATOR
Intervention: Both EF and SF
Number of subjects: 582
Study 33740496 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 12 weeks of a structured physical exercise program, consisting of two 60‐min weekly sessions including warm-up, aerobic training, resistance training, and stretching.
Number of subjects: 21
Study 33740496 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no exercise and maintenance of usual activities.
Number of subjects: 21
Study 33740496 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - 12 weeks of a structured physical exercise program.
Number of subjects: 21
Study 34715810 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery + intraoperative HIPEC (cisplatin 75 mg/m2 at 42°C for 90 min) and postoperative FLOT (Docetaxel 50 mg/m2; Oxaliplatin 85 mg/m2; Leucovorin 200 mg/m2; 5-FU 2600 mg/m2, q2wk)
Number of subjects: 200
Study 34715810 — intervention group
Group type: COMPARATOR
Intervention: Surgery only and postoperative FLOT (control arm)
Number of subjects: 200
Study 36195931 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based coping strategies
Number of subjects: 2
Study 36195931 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 34151646 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based exercise training program
Number of subjects: 60
Study 34151646 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 individuals without IC)
Number of subjects: 60
Study 35101369 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Tongxin Dropping Pill (STDP) plus dual antiplatelet therapy (DAPT) with clopidogrel and aspirin
Number of subjects: 118
Study 35101369 — intervention group
Group type: COMPARATOR
Intervention: DAPT alone (Control)
Number of subjects: 118
Study 33917999 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle coaching
Number of subjects: 0
Study 35855835 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedforward control combined with 4F management and early healing/repairing training
Number of subjects: 100
Study 35855835 — intervention group
Group type: COMPARATOR
Intervention: 4F management combined with feedforward control nursing mode
Number of subjects: 100
Study 35855835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing quality of watching, noticing, or making a statement group
Number of subjects: 100
Study 33588798 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS intervention (5 sessions)
Number of subjects: 102
Study 33588798 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS intervention
Number of subjects: 102
Study 32648924 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention (n = 722) including heart failure education, telephone check-ins, and a wireless telemonitoring system
Number of subjects: 538
Study 32648924 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n = 715)
Number of subjects: 538
Study 34224251 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO): 100 mg/kg SC q24 h
Number of subjects: 66
Study 34224251 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP): oral, 75 mg/kg
Number of subjects: 66
Study 34224251 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine + Phlebotomy (DFO + F): 100 mg/kg SC q24 h with phlebotomy
Number of subjects: 66
Study 34224251 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone + Phlebotomy (DFP + F): oral, 75 mg/kg with phlebotomy
Number of subjects: 66
Study 32601123 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (AEP scores made available to treating physicians)
Number of subjects: 222
Study 32601123 — intervention group
Group type: COMPARATOR
Intervention: Control group (AEP scores not made available to treating physicians)
Number of subjects: 222
Study 34784889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block (PVB) with 30 mL of 0.5% ropivacaine
Number of subjects: 60
Study 34784889 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided retrolaminar block (RLB) with 30 mL of 0.5% ropivacaine
Number of subjects: 60
Study 32029355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat coadministered with digoxin
Number of subjects: 96
Study 32029355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat coadministered with metoprolol
Number of subjects: 96
Study 32029355 — intervention group
Group type: EXPERIMENTAL
Intervention: Eliglustat coadministered with oral contraceptives
Number of subjects: 96
Study 32029355 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-reducing agents coadministered with eliglustat
Number of subjects: 96
Study 32029355 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tolerability of eliglustat
Number of subjects: 96
Study 36351326 — intervention group
Group type: EXPERIMENTAL
Intervention: Early time-restricted eating (eTRE) with a daily 6-hour eating window
Number of subjects: 24
Study 36351326 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) with a daily 16-hour eating window
Number of subjects: 24
Study 32048426 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasound measurements of fetal brain structures (POF, SF, AV, PV, CM)
Number of subjects: 442
Study 36090126 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Floss® (Oral-B)
Number of subjects: 34
Study 36090126 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik® water flosser
Number of subjects: 34
Study 36090126 — intervention group
Group type: COMPARATOR
Intervention: Super Floss® (Oral-B) and Waterpik® water flosser
Number of subjects: 34
Study 35662514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 100
Study 35662514 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.05 mg/kg) + Atropine (0.02 mg/kg)
Number of subjects: 100
Study 35662514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 100
Study 35662514 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 100
Study 35662514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex and Neostigmine
Number of subjects: 100
Study 34949970 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic diaphragm excursion during forced deep breathing (Df)
Number of subjects: 64
Study 34949970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (FVC, FEV1.0, PEF, Pimax, WRmax, VO2max)
Number of subjects: 64
Study 34949970 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic diaphragm excursion during quiet breathing (Dq)
Number of subjects: 64
Study 32792679 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model for differentiating KD from sepsis
Number of subjects: 420
Study 32792679 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory markers (WBC, anemia, PCT, CRP, albumin, ALT)
Number of subjects: 420
Study 36413252 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized dosing of pemetrexed (n = 37)
Number of subjects: 81
Study 36413252 — intervention group
Group type: COMPARATOR
Intervention: Standard BSA-based dosing (n = 44)
Number of subjects: 81
Study 32654541 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous device closure (group A)
Number of subjects: 110
Study 32654541 — intervention group
Group type: COMPARATOR
Intervention: Surgical repair via median sternotomy (group B)
Number of subjects: 110
Study 33290238 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 153
Study 33290238 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 153
Study 35053326 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin group (dual marker strategy of copeptin and hs‐cTnT at presentation)
Number of subjects: 893
Study 35053326 — intervention group
Group type: COMPARATOR
Intervention: Standard group (serial hs‐cTnT testing)
Number of subjects: 893
Study 35053326 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin group (per-protocol analysis)
Number of subjects: 893
Study 34375387 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Weight for Living (HWL)
Number of subjects: 238
Study 34375387 — intervention group
Group type: COMPARATOR
Intervention: modified Diabetes Prevention Program (m-DPP)
Number of subjects: 238
Study 34657872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS)
Number of subjects: 41
Study 34657872 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal bracing (AB)
Number of subjects: 41
Study 34657872 — intervention group
Group type: COMPARATOR
Intervention: Abdominal drawing‐in maneuver (ADIM)
Number of subjects: 41
Study 33820919 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial liver support system (ALSS) treatment
Number of subjects: 375
Study 33820919 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree based on multivariate logistic regression model using CTP score and RPTB
Number of subjects: 375
Study 34363198 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist pre-treatment for 60 days
Number of subjects: 814
Study 34363198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 814
Study 34363198 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey response regarding COVID-19 impact
Number of subjects: 814
Study 35066251 — intervention group
Group type: EXPERIMENTAL
Intervention: SYSU‐NEP virtual patients (VPs)
Number of subjects: 90
Study 35066251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 34779691 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized executive cognitive intervention with lab‐based tasks
Number of subjects: 0
Study 34779691 — intervention group
Group type: COMPARATOR
Intervention: Control group (low‐performance intervention)
Number of subjects: 0
Study 34559902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib (IXA), Pomalidomide (POM), Dexamethasone (DEX)
Number of subjects: 29
Study 34927308 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 1008
Study 34927308 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta
Number of subjects: 1008
Study 34927308 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glatiramer acetate and interferon beta
Number of subjects: 1008
Study 33191846 — intervention group
Group type: EXPERIMENTAL
Intervention: iddEPC group (n=424) - neo-adjuvant dose-dense, dose-intensified epirubicin, paclitaxel, and cyclophosphamide
Number of subjects: 853
Study 33191846 — intervention group
Group type: COMPARATOR
Intervention: paclitaxel, non-pegylated doxorubicin, and carboplatin group (n=429)
Number of subjects: 853
Study 33191846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (iddEPC and paclitaxel, non-pegylated doxorubicin, and carboplatin)
Number of subjects: 853
Study 33191846 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 6 weeks after treatment initiation
Number of subjects: 853
Study 33191846 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin measured at 6 weeks after treatment initiation
Number of subjects: 853
Study 33191846 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 853
Study 616117430 — intervention group
Group type: EXPERIMENTAL
Intervention: Copaxone (glatiramer acetate), weekly subcutaneous injections for 12 weeks
Number of subjects: 11
Study 616117430 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 11
Study 36252599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin plus doxorubicin (2.0 mg/m2 plus 40.0 mg/m2 on day 1 of 21-day cycles)
Number of subjects: 613
Study 36252599 — intervention group
Group type: COMPARATOR
Intervention: Control (topotecan 1.5 mg/m2 on days 1-5 of 21-day cycles; or CAV: cyclophosphamide 1000 mg/m2, doxorubicin 45.0 mg/m2, and vincristine 2.0 mg on day 1 of 21-day cycles)
Number of subjects: 613
Study 36252599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin plus doxorubicin
Number of subjects: 613
Study 36252599 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 613
Study 33345481 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese therapy of tonifying the kidney and invigorating blood circulation (TKIB), n = 22
Number of subjects: 42
Study 33345481 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral tamoxifen tablets and vitamin E capsules), n = 20
Number of subjects: 42
Study 35748715 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 30
Study 34160459 — intervention group
Group type: EXPERIMENTAL
Intervention: Food preparation program (n=11)
Number of subjects: 22
Study 34160459 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 22
Study 35248121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application
Number of subjects: 130
Study 35248121 — intervention group
Group type: COMPARATOR
Intervention: Non-tourniquet application
Number of subjects: 130
Study 32485112 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections (4 injections, 14 days apart)
Number of subjects: 40
Study 32485112 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections (4 injections of saline, <0.5 mL, under the skin, 14 days apart)
Number of subjects: 40
Study 32485112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PRP and placebo groups
Number of subjects: 40
Study 35534905 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified nominal group technique
Number of subjects: 0
Study 33245866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg to 2000 mg based on bodyweight and haemoglobin concentration)
Number of subjects: 230
Study 33245866 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (three dried ferrous sulphate tablets of 200 mg containing 60 mg of elemental iron and 5 mg of folic acid every morning for 3 months)
Number of subjects: 230
Study 36351736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low and high frequencies NMES
Number of subjects: 56
Study 36351736 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency NMES
Number of subjects: 56
Study 36351736 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency NMES
Number of subjects: 56
Study 36351736 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 56
Study 34128358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal carrageenan administered three times per day for 7 days
Number of subjects: 0
Study 34128358 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal carrageenan
Number of subjects: 0
Study 34128358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32815394 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in lectures or events related to dementia
Number of subjects: 586
Study 32815394 — intervention group
Group type: EXPERIMENTAL
Intervention: Female students
Number of subjects: 586
Study 32815394 — intervention group
Group type: COMPARATOR
Intervention: High school students
Number of subjects: 586
Study 35588291 — intervention group
Group type: EXPERIMENTAL
Intervention: AR board game
Number of subjects: 600
Study 35588291 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper board games
Number of subjects: 600
Study 35588291 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 600
Study 33615722 — intervention group
Group type: COMPARATOR
Intervention: FV diet
Number of subjects: 459
Study 33615722 — intervention group
Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 459
Study 33114125 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM half-shell mussel
Number of subjects: 8
Study 33114125 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM powder
Number of subjects: 8
Study 33114125 — intervention group
Group type: COMPARATOR
Intervention: GSM oil
Number of subjects: 8
Study 36356514 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 64
Study 36356514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 34472754 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 94
Study 34472754 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEAS
Number of subjects: 94
Study 32349134 — intervention group
Group type: EXPERIMENTAL
Intervention: H2S stimulation
Number of subjects: 23
Study 32349134 — intervention group
Group type: EXPERIMENTAL
Intervention: PEA stimulation
Number of subjects: 23
Study 32349134 — intervention group
Group type: COMPARATOR
Intervention: CO2 irritation
Number of subjects: 23
Study 32349134 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation (H2S vs PEA)
Number of subjects: 23
Study 35286843 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24Fc 480 mg
Number of subjects: 234
Study 35286843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 32480076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training using Hybrid Assistive Limb (HAL)
Number of subjects: 27
Study 32480076 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 27
Study 36608973 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced mental reinstatement (EMR)
Number of subjects: 45
Study 36608973 — intervention group
Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 45